I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

AMCP 2023

-
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features

Mar 22 / Roche and Genentech
Long-term Trends in Healthcare Resource Use for US Medicare Patients Following Alzheimer’s Disease Diagnosis
A retrospective observational study using the 100% fee-for-service Medicare claims database from 2005 to 2020 was conducted to examine the relationship between diagnosis and healthcare resource use (HRU) covered by Medicare during the 5 years preceding and 14 years following incident diagnosis. The analysis found that AD requires a large amount of overall HRU days per year, and HRU generally increases over several years prior to AD diagnosis.

Sign up or login to unlock the full suite of MEDICALLY features

Mar 22 / Roche and Genentech
Racial Health Disparities in Black People With Alzheimer’s Disease: Evidence of Diagnosis at a Later Stage
This analysis of data from a real-world, cross-sectional survey of HCPs and their patients with cognitive impairment in the US between January and May 2016 found that Black patients had lower MMSE scores at initial diagnosis of MCI due to AD or AD dementia compared with those of non-Hispanic White patients.

Sign up or login to unlock the full suite of MEDICALLY features

Mar 22 / Roche and Genentech
Budget impact of maintaining atezolizumab as a preferred treatment option for adjuvant treatment of patients with early non-small cell lung cancer (eNSCLC)
This poster reports on the budgetary impact of maintaining atezolizumab as a preferred treatment option. This budget impact model evaluated maintaining atezolizumab at current market share for patients with eNSCLC compared with a decreased atezolizumab market share due to pembrolizumab adoption in a hypothetical US health plan.